Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. (DRMA) priced its initial public offering on Aug 16, 2021 at $7.00 per share, within its $7.00–$9.00 range, raising $18M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $58.3M. Maxim Group was lead-left underwriter, joined by Brookline and Arcadia. Lowenstein Sandler advised the company and Ellenoff Grossman & Schole advised the underwriters.

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on medical and aesthetic skin conditions. Its lead candidate, DMT310, is a once-weekly topical product derived from a freshwater sponge, in clinical development for acne, psoriasis and rosacea.

Status

IPO

Ticker

DRMA

Exchange

Nasdaq Capital Market

Priced

Aug 16, 2021

IPO price

$7.00

Price range

$7.00–$9.00

Raised

$18M

Market cap at IPO price

$58.3M

First filed

Jun 10, 2021

Underwriters

Maxim Group, Brookline and Arcadia

Company counsel

Lowenstein Sandler

Underwriters' counsel

Ellenoff Grossman & Schole

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.